Dr. Steven Theriault reports

CYTOPHAGE SECURES HEALTH CANADA VALIDATION FOR OVAPHAGE AND PHAGEFEND PRODUCTS FOR USE IN FOOD SAFETY

Cytophage Technologies Ltd. has received two letters of no objection (LONO) from Health Canada regarding its OvaPhage egg surface product and its PhageFend food surface product, marking a major regulatory milestone that will help pave the way for the introduction of innovative, science-driven solutions to enhance food safety in the Canadian market.

• Cytophage receives letters of no objection (LONO) from Health Canada for two of its cutting-edge bacteriophage products;
• Regulatory milestone accelerates Cytophage's path to commercialization and broader market access;
• Canada aligns with the European Union and United States in accepting phage technology, advancing antibiotic-free food solutions.

The LONO validations affirm the safety and efficacy of bacteriophage technology for use in food processing, with OvaPhage now in the final stages of development and advancing toward commercialization.

Phage treatments present an alternative to antibiotics which are known contributors to global antimicrobial resistance (AMR). With these validations, Canada is recognizing and accepting phage technology for food safety and antibiotic-free food options. The LONO notifications are also a crucial step forward in granting phage products market access under a regulated path in Canada.

"This milestone underscores our unwavering commitment to eliminating bacterial diseases and infections," said Dr. Steven Theriault, chief executive officer of Cytophage. "We are proud to lead the way in demonstrating that phage-based solutions can be safe and effective tools for enhancing food safety and security, especially in light of the current Salmonella outbreaks related to pistachio and salami contamination in Canada. By expanding access to our innovative phage products, we aim to significantly reduce reliance on antibiotics in food systems -- offering a sustainable approach to combating the global threat of antimicrobial resistance."

Details on notifications:

• The letters serve as a formal notification by Health Canada's food directorate that the OvaPhage and PhageFend bacteriophage products can be used in food processing and food production.
• Cytophage's application included comprehensive data and scientific evidence demonstrating the safety and efficacy of both products, which were thoroughly evaluated by Health Canada and led to the issuance of the LONO notifications.
• The first LONO notification states that Health Canada evaluated the data provided and concluded that OvaPhage is effective at reducing Salmonella, Escherichia and Shigella bacteria (Enterobacteriaceae) on the surface of eggs.
• The second LONO notification states that Health Canada evaluated the data and concluded that the PhageFend is effective at reducing Salmonella enterica on raw skinless and boneless chicken breasts.

Cytophage is now positioned to finalize the product development of OvaPhage for egg producers and PhageFend for meat processing facilities, enabling a more effective removal of bacteria from surfaces. The company continues to work with its OvaPhage commercial research partner to determine the most effective dosage and application processes for commercial settings.

This regulatory success should pave the way for future approvals of phage products, including those for animal feed and potentially ultimately for therapeutic use in humans, thereby advancing the global fight against antibiotic resistance.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 European Union countries, United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.